Skip to main content
Top
Published in: Journal of Cardiovascular Translational Research 4/2014

01-06-2014

Coronary Vasomotion One Year after Drug-Eluting Stent Implantation: Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents

Authors: Michalis Hamilos, Flavio Ribichini, Miodrag C. Ostojic, Valeria Ferrero, Dejan Orlic, Corrado Vassanelli, Nevena Karanovic, Giovanna Sarno, Thomas Cuisset, Panos E. Vardas, William Wijns

Published in: Journal of Cardiovascular Translational Research | Issue 4/2014

Login to get access

Abstract

First-generation drug-eluting stents (DES) have been associated with impaired localized coronary vasomotion and delayed endothelialization. We aimed to compare coronary vasomotion after implantation of a newer-generation everolimus-eluting stent (EES), with a first-generation paclitaxel-eluting stent (PES). Coronary vasomotion was studied in 19 patients with EES and 13 with PES. Vasomotor response was measured proximally and distally to the stent and in a remote vessel (reference segment). Quantitative coronary angiography was performed offline. Endothelium independent vasomotion did not differ significantly between the two groups. EES showed significant vasodilatation while PES showed vasoconstriction at both proximal (+4.5 ± 3.6 vs −4.2 ± 6.9, p < 0.001) and distal (+4.6 ± 7.9 vs −4.8 ± 9.3, p = 0.003) segments. The reference segment did not show any significant difference in vasodilatation between the two groups (+9.8 ± 6.4 vs +7.2 ± 5.2, p = 0.17). Endothelium-dependent vasomotion at adjacent stent segments is relatively preserved after EES implantation while vasoconstriction was observed after PES implantation.
Literature
1.
go back to reference Stettler, C., Wandel, S., Allemann, S., et al. (2007). Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937–948.PubMedCrossRef Stettler, C., Wandel, S., Allemann, S., et al. (2007). Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937–948.PubMedCrossRef
2.
go back to reference Camenzind, E., Steg, P. G., & Wijns, W. (2007). Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation, 115, 1440–1455. discussion 1455.PubMedCrossRef Camenzind, E., Steg, P. G., & Wijns, W. (2007). Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation, 115, 1440–1455. discussion 1455.PubMedCrossRef
3.
go back to reference Windecker, S., & Jüni, P. (2008). Safety of drug-eluting stents. Nature Clinical Practice. Cardiovascular Medicine, 5, 316–328.PubMedCrossRef Windecker, S., & Jüni, P. (2008). Safety of drug-eluting stents. Nature Clinical Practice. Cardiovascular Medicine, 5, 316–328.PubMedCrossRef
4.
go back to reference Finn, A. V., Nakazawa, G., Joner, M., et al. (2007). Vascular responses to drug eluting stents: importance of delayed healing. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1500–1510.PubMedCrossRef Finn, A. V., Nakazawa, G., Joner, M., et al. (2007). Vascular responses to drug eluting stents: importance of delayed healing. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1500–1510.PubMedCrossRef
5.
go back to reference Van Beusekom, H. M., Saia, F., Zindler, J. D., et al. (2007). Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. European Heart Journal, 28, 974–979.PubMedCrossRef Van Beusekom, H. M., Saia, F., Zindler, J. D., et al. (2007). Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. European Heart Journal, 28, 974–979.PubMedCrossRef
6.
go back to reference Joner, M., Finn, A., Farb, A., et al. (2006). Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. Journal of the American College of Cardiology, 48, 193–202.PubMedCrossRef Joner, M., Finn, A., Farb, A., et al. (2006). Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic risk. Journal of the American College of Cardiology, 48, 193–202.PubMedCrossRef
7.
go back to reference Finn, A. V., Joner, M., Nakazawa, G., et al. (2007). Pathological correlates of late drug-eluting stent thrombosis. Strut coverage as a marker of endothelialization. Circulation, 115, 2435–2441.PubMedCrossRef Finn, A. V., Joner, M., Nakazawa, G., et al. (2007). Pathological correlates of late drug-eluting stent thrombosis. Strut coverage as a marker of endothelialization. Circulation, 115, 2435–2441.PubMedCrossRef
8.
go back to reference Togni, M., Windecker, S., Cocchia, R., et al. (2005). Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. Journal of the American College of Cardiology, 46, 231–236.PubMedCrossRef Togni, M., Windecker, S., Cocchia, R., et al. (2005). Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. Journal of the American College of Cardiology, 46, 231–236.PubMedCrossRef
9.
go back to reference Hofma, S., Van der Giessen, W., Van Dalen, B., et al. (2006). Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal, 27, 166–170.PubMedCrossRef Hofma, S., Van der Giessen, W., Van Dalen, B., et al. (2006). Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. European Heart Journal, 27, 166–170.PubMedCrossRef
10.
go back to reference Togni, M., Räber, L., Cocchia, R., et al. (2007). Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. International Journal of Cardiology, 120, 212–220.PubMedCrossRef Togni, M., Räber, L., Cocchia, R., et al. (2007). Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. International Journal of Cardiology, 120, 212–220.PubMedCrossRef
11.
go back to reference Hamilos, M. I., Ostojic, M., Beleslin, B., NOBORI CORE investigators, et al. (2008). Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. Journal of the American College of Cardiology, 51, 2123–2129.PubMedCrossRef Hamilos, M. I., Ostojic, M., Beleslin, B., NOBORI CORE investigators, et al. (2008). Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. Journal of the American College of Cardiology, 51, 2123–2129.PubMedCrossRef
12.
go back to reference Hamilos, M., Sarma, J., Ostojic, M., et al. (2008). Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circulation. Cardiovascular Interventions, 1, 193–200.PubMedCrossRef Hamilos, M., Sarma, J., Ostojic, M., et al. (2008). Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circulation. Cardiovascular Interventions, 1, 193–200.PubMedCrossRef
13.
go back to reference Wiemer, M., Seth, A., Chandra, P., et al. (2008). Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. American Heart Journal, 156, 751–757.PubMedCrossRef Wiemer, M., Seth, A., Chandra, P., et al. (2008). Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. American Heart Journal, 156, 751–757.PubMedCrossRef
14.
go back to reference Torguson, R., & Waksman, R. (2008). Overview of the 2007 food and drug administration circulatory system devices panel meeting on the Xience V everolimus-eluting coronary stent. American Journal of Cardiology, 102, 1624–1630.PubMedCrossRef Torguson, R., & Waksman, R. (2008). Overview of the 2007 food and drug administration circulatory system devices panel meeting on the Xience V everolimus-eluting coronary stent. American Journal of Cardiology, 102, 1624–1630.PubMedCrossRef
15.
go back to reference Stone, G. W., Midei, M., Newman, W., SPIRIT III Investigators, et al. (2009). Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation, 119, 680–686.PubMedCrossRef Stone, G. W., Midei, M., Newman, W., SPIRIT III Investigators, et al. (2009). Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation, 119, 680–686.PubMedCrossRef
16.
go back to reference Stone, G. W., Rizvi, A., Newman, W., SPIRIT IV Investigators, et al. (2010). Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New England Journal of Medicine, 362, 1663–1674.PubMedCrossRef Stone, G. W., Rizvi, A., Newman, W., SPIRIT IV Investigators, et al. (2010). Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New England Journal of Medicine, 362, 1663–1674.PubMedCrossRef
17.
go back to reference Onuma, Y., Kukreja, N., Piazza, N., Interventional Cardiologists of the Thoraxcenter (2000 to 2007), et al. (2009). The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. Journal of the American College of Cardiology, 54, 269–276.PubMedCrossRef Onuma, Y., Kukreja, N., Piazza, N., Interventional Cardiologists of the Thoraxcenter (2000 to 2007), et al. (2009). The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. Journal of the American College of Cardiology, 54, 269–276.PubMedCrossRef
18.
go back to reference Kedhi, E., Joesoef, K. S., McFadden, E., et al. (2010). Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 375, 201–209.PubMedCrossRef Kedhi, E., Joesoef, K. S., McFadden, E., et al. (2010). Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet, 375, 201–209.PubMedCrossRef
19.
go back to reference Axel, D. I., Kunert, W., Goggelmann, C., et al. (1997). Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 96, 636–645.PubMedCrossRef Axel, D. I., Kunert, W., Goggelmann, C., et al. (1997). Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation, 96, 636–645.PubMedCrossRef
20.
go back to reference John, M. C., Wessely, R., Kastrati, A., et al. (2008). Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC. Cardiovascular Interventions, 1, 535–544.PubMedCrossRef John, M. C., Wessely, R., Kastrati, A., et al. (2008). Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC. Cardiovascular Interventions, 1, 535–544.PubMedCrossRef
21.
go back to reference Joner, M., Nakazawa, G., Finn, A. V., et al. (2008). Endothelial cell recovery between comparator polymer-based drug-eluting stents. Journal of the American College of Cardiology, 52, 333–342.PubMedCrossRef Joner, M., Nakazawa, G., Finn, A. V., et al. (2008). Endothelial cell recovery between comparator polymer-based drug-eluting stents. Journal of the American College of Cardiology, 52, 333–342.PubMedCrossRef
22.
go back to reference Serruys, P. W., Onuma, Y., Ormiston, J. A., et al. (2010). Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation, 122, 2301–2312.PubMedCrossRef Serruys, P. W., Onuma, Y., Ormiston, J. A., et al. (2010). Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation, 122, 2301–2312.PubMedCrossRef
23.
go back to reference Simon, C., Palmaz, J. C., & Sprague, E. A. (2000). Influence of topography on endothelialization of stents: clues for new designs. Journal of Long-Term Effects of Medical Implants, 10, 143–151.PubMedCrossRef Simon, C., Palmaz, J. C., & Sprague, E. A. (2000). Influence of topography on endothelialization of stents: clues for new designs. Journal of Long-Term Effects of Medical Implants, 10, 143–151.PubMedCrossRef
Metadata
Title
Coronary Vasomotion One Year after Drug-Eluting Stent Implantation: Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents
Authors
Michalis Hamilos
Flavio Ribichini
Miodrag C. Ostojic
Valeria Ferrero
Dejan Orlic
Corrado Vassanelli
Nevena Karanovic
Giovanna Sarno
Thomas Cuisset
Panos E. Vardas
William Wijns
Publication date
01-06-2014
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 4/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-014-9568-2

Other articles of this Issue 4/2014

Journal of Cardiovascular Translational Research 4/2014 Go to the issue